Elsevier

Clinics in Chest Medicine

Volume 22, Issue 4, 1 December 2001, Pages 637-649
Clinics in Chest Medicine

SINGLE-BREATH CARBON MONOXIDE DIFFUSING CAPACITY*,

https://doi.org/10.1016/S0272-5231(05)70057-5Get rights and content

Section snippets

PATHWAY FOR DIFFUSION

The pathway for diffusion of O2 and CO, schematically illustrated in Figure 1, is helpful in understanding the test and its limitations and can aid in interpretation of the test. Oxygen and CO simultaneously diffuse across the alveolar capillary membrane, across a thin layer of plasma, across a red blood cell membrane, and within the red blood cell until they encounter and compete for the same hemoglobin binding sites. In a landmark paper published in 1957, Roughton and Forster40, 62 described

THE SINGLE-BREATH, BREATH-HOLDING MEASUREMENT OF DIFFUSING CAPACITY

Although several methods of measuring DlCO have been described in the literature, this article addresses only the single-breath with breath-holding method because: (1) it is the method most commonly used for day-to-day clinical testing today. (2) The testing procedure has been standardized by several respiratory and thoracic societies. (3) There are well-defined reference values and lower limits for healthy subjects. (4) Most commercial instruments use this method. (5) Most studies

INTERPRETING DIFFUSING CAPACITY—TEST QUALITY AND REFERENCE VALUES

The ATS published a guideline on interpretive issues for lung function testing, including the selection of reference values.8 The first step in interpretation is to evaluate and comment on test quality, looking at the sources of variability just addressed. Specifically, the tracings should be evaluated for: (1) the adequacy and timing of the inspired volume of test gas (criterion: an inspired volume > 90% of the largest previously measured vital capacity inhaled within 2.5 seconds in

APPROACH TO DISEASE CONDITIONS THAT MAY ALTER DIFFUSING CAPACITY

The Roughton-Forster equation may not be entirely correct conceptually37 but it does provide a nice guide to the effect of most pulmonary diseases on DlCO. Consider each term in the equation: Dm is altered by surface area, alveolar capillary membrane thickness, and physical diffusivity of tissue. Diseases that alter any or all of these elements reduce DlCO. These effects would reduce DlCO in pulmonary fibrosis and emphysema. Theta (θ) is altered by elements that affect the number of binding

SUMMARY

Measurement of DlCO remains a clinically useful way to assess transfer of gases across the lung. It is important, however, to be vigilant in controlling the sources of variation and to be aware of those that remain when interpreting the measured values.

Acknowledgment

The authors thank Janet Embry for editorial assistance in revising the manuscript.

First page preview

First page preview
Click to open first page preview

References (75)

  • D.C. Johnson

    Importance of adjusting carbon monoxide diffusing capacity (DLCO and carbon monoxide transfer coefficient (KCO) for alveolar volume

    Respir Med

    (2000)
  • K. Jules-Elysee et al.

    Bleomycin-induced pulmonary toxicity

    Clin Chest Med

    (1990)
  • B. Mettauer et al.

    Lung membrane diffusing capacity, heart failure, and heart transplantation

    Am J Cardiol

    (1999)
  • A.W. Sheel et al.

    The time course of pulmonary diffusing capacity for carbon monoxide following short duration high intensity exercise

    Respir Physiol

    (1998)
  • H.E. Solberg et al.

    Reference values

    Advances in Clin Chem

    (1989)
  • H. Stam et al.

    Evaluation of diffusing capacity in patients with a restrictive disease

    Chest

    (2000)
  • H.S.K. Wimalaratna et al.

    Measurement of diffusing capacity in pulmonary embolism

    Respir Med

    (1989)
  • U. Akesson et al.

    Changes in transfer factor of the lung in response to bronchodilation

    Clin Physiol

    (2000)
  • O.A. Al-Rawas et al.

    The alveolar-capillary diffusing capacity and the pulmonary capillary blood volume in heart transplant candidates

    Heart

    (2000)
  • American Thoracic Society

    Single-breath carbon monoxide diffusing capacity (Transfer factor). Recommendations for a standard technique

    Am Rev Respir Dis

    (1987)
  • American Thoracic Society

    Single-breath carbon monoxide diffusing capacity (Transfer factor). Recommendations for a standard technique—1995 update

    Am J Respir Crit Care Med

    (1995)
  • American Thoracic Society Statement

    Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease

    Am J Respir Crit Care Med

    (1995)
  • M.R. Becklake et al.

    Lung function testing: Selection of reference values and interpretative strategies. Official Statement of the American Thoracic Society

    Am Rev Respir Dis

    (1991)
  • K.S. Bhalla et al.

    Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support

    Am J Respir Crit Care Med

    (2000)
  • British Thoracic Guidelines for the Management of Chronic Obstructive Pulmonary Disease

    Thorax

    (1997)
  • D.J. Chinn et al.

    Accuracy of gas analysis in lung function laboratories

    Thorax

    (1986)
  • D.J. Chinn et al.

    Measurement technique influences the response of transfer factor (TLCO) to salbutamol in patients with airflow obstruction

    Eur Respir J

    (1997)
  • D.J. Chinn et al.

    Transfer factor (diffusing capacity) standardized for alveolar volume: Validation, reference values and applications of a new linear model to replace Kco (Tl/Va)

    Eur Respir J

    (1996)
  • F.F. Cinkotai et al.

    Diurnal variation in pulmonary diffusing capacity for carbon monoxide

    J Appl Physiol

    (1966)
  • J. Clausen et al.

    Interlaboratory comparisons of pulmonary function testing

    Am Rev Respir Dis

    (1984)
  • R.F. Coburn et al.

    Considerations of the physiological variables that determine the blood carboxyhemoglobin in man

    J Clin Invest

    (1965)
  • J.E. Cotes et al.

    Official Statement of the European Respiratory Society: Standardization of the measurement of transfer factor (Diffusing Capacity)

    Eur Respir J

    (1993)
  • T.D. Coulter et al.

    What causes an elevated diffusing capacity

    Respir Care Clin N Am

    (2000)
  • R.O. Crapo

    Normal cardiopulmonary physiology during pregnancy

    Clin Obstet Gynecol

    (1996)
  • R.O. Crapo

    Carbon monoxide diffusing capacity (transfer factor)

    Seminars in Respiratory and Critical Care Medicine

    (1998)
  • W.J. Daly et al.

    The pressure volume relationship of normal pulmonary capillary bed

    J Clin Invest

    (1965)
  • G.R. Epler et al.

    Normal chest roentgenograms in chronic diffuse infiltrative lung disease

    N Engl J Med

    (1978)
  • Cited by (44)

    • Effect of rituximab on pulmonary function in patients with rheumatoid arthritis

      2016, Pulmonary Pharmacology and Therapeutics
      Citation Excerpt :

      The aim of the present study was to investigate the prevalence of pulmonary function changes in patients with RA during RTX therapy. Since DLCO decline is one of the earliest, although nonspecific, signs of interstitial lung disease, we performed DLCO measurements in addition to spirometry [29]. Furthermore, we attempted to identify risk factors for the development of pulmonary function changes.

    • Respiratory Physiology

      2016, Smith's Anesthesia for Infants and Children, Ninth Edition
    • Pulmonary involvement in Fabry disease: Overview and perspectives

      2013, European Journal of Internal Medicine
      Citation Excerpt :

      Considering all available data concerning DLCO measurements in Fabry patients, 15.7% (11/70) showed a significant impairment (Table 1), defined as DLCO < 80% of the predicted value [41]. An impaired DLCO is one of the earliest, although nonspecific, manifestations of interstitial lung diseases [42]. In two case reports of two female Fabry patients, an impaired gas exchange and patchy ground-glass opacities on the chest CT were reported [8,13].

    • When Should Pulmonary Function Tests Be Performed Preoperatively?

      2013, Evidence-Based Practice of Anesthesiology
    • Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease

      2012, Respiratory Medicine
      Citation Excerpt :

      The cohort in this retrospective study was comprised of patients who presented to our center between January 2008 and January 2010 for evaluation of unexplained respiratory symptoms and who met the following inclusion criteria: (1) age >18 years; (2) anti-CCP ≥20 international units (IU) in our laboratory; (3) absence of RA or other CTD; (4) absence of a history of (or currently present) joint symptoms or signs suggestive of inflammatory arthritis; (5) clinical evidence of lung disease (respiratory symptoms or pulmonary physiologic, gas exchange, or chest imaging abnormalities); and (6) thoracic high-resolution computed tomography (HRCT) scan available for review. Each subject underwent pulmonary physiology testing [based on current accepted methodology11–13 and with results expressed as a percentage of the predicted value for age, gender, and height], and thoracic HRCT as part of their routine clinical evaluation. This study was approved by the National Jewish Health Institutional Review Board (IRB) (protocol HS #2454) and due to the retrospective nature of the study; the requirement for informed consent was waived.

    • Pulmonary Function Testing

      2012, Clinical Respiratory Medicine: Fourth Edition
    View all citing articles on Scopus
    *

    *STPD = standard temperature pressure dry

    Address reprint requests to Robert O. Crapo, MD, Pulmonary Division, LDS Hospital, 8th Ave and C Street, Salt Lake City, UT 84143, e-mail: ldrcrapo@ihc.com

    View full text